Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Sarah, Sammons"'
Autor:
Alex Schick, Sara Hardy, Myla Strawderman, Dandan Zheng, Michael Cummings, Michael T. Milano, Allison Magnuson, Jacqueline Behr, Sarah Sammons, Kenneth Usuki, Nimish Mohile, Ruth O’Regan, Carey K. Anders, David Hicks, Ajay Dhakal
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institut
Externí odkaz:
https://doaj.org/article/08d73478060c4e5ba9c384f5637ac6ea
Autor:
Stacey Pan, Jayant Y. Gadrey, Sarah Sammons, Nancy U. Lin, Sara M. Tolaney, Paolo Tarantino, Ilana Schlam
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. De
Externí odkaz:
https://doaj.org/article/228052a30a8c47edb31a02d73a0d9afb
Autor:
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E. D. Van Swearingen, Sara M. Tolaney, Mustafa Khasraw, Carey K. Anders, Christopher D. Lascola, Liangge Hsu, Nancy U. Lin, Sarah Sammons
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%)
Externí odkaz:
https://doaj.org/article/c1b60de0ae2644269e08499f1c0de607
Autor:
Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Evanthia T. Roussos Torres
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundData supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune
Externí odkaz:
https://doaj.org/article/8b0d35ab3ce5400f8a02d8f094918d24
Autor:
Ipshita Prakash, N. Ben Neely, Samantha M. Thomas, Sarah Sammons, Rachel C. Blitzblau, Gayle A. DiLalla, Terry Hyslop, Carolyn S. Menendez, Jennifer K. Plichta, Laura H. Rosenberger, Oluwadamilola M. Fayanju, E. Shelley Hwang, Rachel A. Greenup
Publikováno v:
Cancer Medicine, Vol 11, Iss 4, Pp 1099-1108 (2022)
Abstract Background Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among
Externí odkaz:
https://doaj.org/article/17bacb17c23f4bb29164cca8bf68449c
Autor:
Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine Pogue-Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A. A. Vignali, George C. Tseng, Leisha A. Emens, Peter C. Lucas, Kimberly L. Blackwell, Steffi Oesterreich, Adrian V. Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast cancer lesions remaining largely und
Externí odkaz:
https://doaj.org/article/c2fc89921000427ea6b01395b0309364
Autor:
Laura Noteware, Gloria Broadwater, Nicole Dalal, Laura Alder, James E. Herndon II, Scott Floyd, William Giles, Amanda E. D. Van Swearingen, Carey K. Anders, Sarah Sammons
Publikováno v:
Breast Cancer Research and Treatment. 197:425-434
Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never been p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef23fb8edd95e74d95de8f199126b754
https://doi.org/10.1007/s10549-022-06799-7
https://doi.org/10.1007/s10549-022-06799-7
Autor:
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E.D. Van Swearingen, Yanzhi Wang, Alyssa Pereslete, Liangge Hsu, Pamela J. DiPiro, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S. Raghavendra, Maria Gule-Monroe, Rashmi K. Murthy, Eric P. Winer, Carey K. Anders, Jean J. Zhao, Nancy U. Lin
Publikováno v:
Clin Cancer Res
Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd732bc462df40bf3795d7807bf20c2f
https://doi.org/10.1158/1078-0432.ccr-22-1138
https://doi.org/10.1158/1078-0432.ccr-22-1138
Autor:
Donald P. McDonnell, John D. Norris, Ching-yi Chang, Suzanne E. Wardell, Sarah Sammons, Myles Brown, Rinath Jeselsohn, Steffi Oesterreich, Sandeep Artham, Rachid Safi, Sunghee Park, Jennifer G. Baker, Kaitlyn J. Andreano
The estrogen receptor (ER/ESR1) is expressed in a majority of breast cancers and drugs that inhibit ER signaling are the cornerstone of breast cancer pharmacotherapy. Currently, aromatase inhibitors are the frontline endocrine interventions of choice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e02837e68b422e6bbee28a3fb031fa
https://doi.org/10.1158/1535-7163.c.6542740
https://doi.org/10.1158/1535-7163.c.6542740
Autor:
Donald P. McDonnell, John D. Norris, Ching-yi Chang, Suzanne E. Wardell, Sarah Sammons, Myles Brown, Rinath Jeselsohn, Steffi Oesterreich, Sandeep Artham, Rachid Safi, Sunghee Park, Jennifer G. Baker, Kaitlyn J. Andreano
Supplemental Figure 1: Structures of clinically relevant compounds used in this study. Supplemental Figure 2: Cells expressing both the ERWT and ERmuts have similar pharmacological responses to antiestrogens when compared to cells only expressing ERW
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b94a5c88ad45aa9476da6ffd8fc2fb
https://doi.org/10.1158/1535-7163.22520716
https://doi.org/10.1158/1535-7163.22520716